Europe's new health assessment system could be a game-changer
To see the new approach – in effect since January – in action, look no further than a modest but revealing spreadsheet on the European Commission's webpage. It lists the joint clinical assessments (JCAs) now underway. Currently, three new cancer drugs are being evaluated by national health authorities, with their assessments soon to be shared across all EU countries.
At present, each EU member state maintains its own evaluation committees and criteria. For smaller or less affluent countries, it remains a resource-heavy challenge to assess how a new product performs compared to existing alternatives – and whether it justifies the potential cost.
On Wednesday, a conference organised by the Commission's health department marked the implementation of the Health Technology Assessment Regulation (HTA) – which governs this approach – as the start of 'a new era of collaboration.' HTA typically begins after a medicine or device has been approved and provides national decision-makers with evidence on whether – and how - to offer it to their populations.
While the regulation stops short of harmonising the full HTA process, it introduces a major innovation: joint clinical assessments. These evaluations review existing research on a product's clinical effectiveness. Roisin Adams, Chair of the Member State Coordination Group on HTA, underscored their importance in helping countries rein in spiraling healthcare costs.
'Many countries are still recovering from global events, not least the pandemic. We need to make smart decisions – and for that, we need solid information,' she said.
In this initial phase, only new cancer drugs and advanced therapy medicinal products will trigger a joint assessment, coordinated by the Member State Coordination Group and supported by HTA experts at the European Commission. According to Adams, around 25 medicines are expected to undergo assessment in 2025. High-risk medical devices, such as implantable cardiac defibrillators, will be added in 2026, orphan drugs in 2028, and by 2030, all new medicinal products will be covered by the regulation. Hope for cancer patients Patient organisations are hopeful the new approach will deliver.
'It's meant to accelerate access and increase transparency,' said Antonella Cardone of Cancer Patients Europe. Once a joint assessment is published, patient advocates hope to put more pressure on national systems that are slow to make new treatments available.
For now, though, the regulation is creating additional work for national HTA bodies.
Pedro Facon, General Manager of Belgium's National Health Institute and head of the EU-wide consortium streamlining HTA procedures, likened the situation to parenting a toddler: 'As a national HTA institution, we're faced with new, complex procedures – all while continuing our regular work.' He also noted that agencies leading assessments are only reimbursed two years later – a practical hurdle for already stretched institutions.
Still, many experts say the long-term gains outweigh the short-term strain.
Sabine Vogler, Head of Pharmacoeconomics at Austria's National Public Health Institute, acknowledged the difficulty of aligning diverse systems, but called the initiative 'an important step forward,' especially for smaller and less resourced countries.
'Ultimately, this should save time, since countries can adapt joint assessments to fit their national context,' she said.
Maya Matthews, Deputy Director and Head of HTA at the European Commission's DG SANTE, highlighted the broader potential. Her team, she stressed, is doing far more than 'niche work.' HTA could be 'the key to some of the big discussions we're having – about access, unmet needs, and reducing complexity.'
One thing is certain: the future of EU health cooperation may well be built, at least in part, on carefully crafted Excel sheets.
(de)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Euractiv
3 days ago
- Euractiv
Ireland publishes National Drugs Strategy as ministers battle rising cocaine use
Dublin - Ireland's health ministers have released an independent evaluation of the country's National Drugs Strategy (NDS), 'Reducing Harm, Supporting Recovery 2017–2025', highlighting progress in harm reduction and international alignment, while also identifying areas for structural reform. The report, commissioned by the Department of Health and conducted by Grant Thornton, assesses the strategy across four key domains: impact, governance, performance, and coherence with international policy frameworks. It fulfils a commitment made in the Programme for Government and arrives as policymakers prepare to draft a successor strategy by the end of 2025. The evaluation finds that the NDS has made 'notable progress in advancing a health-led approach,' particularly through the expansion of harm reduction measures such as naloxone distribution, needle exchange programmes, and drug-checking services. On governance, the report cites the establishment of strategic implementation groups and enhanced interagency collaboration at the local level as key achievements. These developments, it notes, have enabled 'more responsive and context-sensitive service delivery.' Performance metrics show improved data collection and monitoring. Shifting trends Cocaine emerged as the most common primary drug reported in treatment cases in 2024, underscoring a shift in Ireland's drug use profile. Ireland's latest drug use figures, published in 2025 by the Health Research Board, reveal a shifting landscape in substance use, with cannabis and cocaine remaining the most prevalent illicit drugs. Based on data from the 'Healthy Ireland Survey 2023', 7.8% of adults reported using cannabis in the past year, while cocaine use rose to 4.4%, particularly among those aged 25–34. Sedative and tranquilliser use stood at 2.5%, with higher rates among women and older adults. The report also highlights a rise in polydrug use and a strong correlation between drug use and other risk behaviours, including tobacco and alcohol consumption. EU drug strategy alignment Internationally, the strategy is deemed well-aligned with the EU Drugs Strategy and Action Plan 2021–2025, with Ireland's contributions to early warning systems and multilateral research initiatives receiving particular praise. However, the review also identifies persistent challenges, including fragmented delivery of prevention and early intervention services, and a need for alternatives to coercive sanctions. It outlines 10 strategic recommendations to guide the next phase of policy development. Minister for Health Jennifer Carroll MacNeill welcomed the report's focus on equity and access, noting alignment with ongoing Sláintecare reforms. 'The establishment of new HSE health regions presents a valuable opportunity to tailor drug treatment services to population needs and to ensure that both existing and new funding is allocated effectively and transparently,' she said. Carroll MacNeill also highlighted the importance of cross-border and EU collaboration: 'The upcoming Irish Presidency of the EU offers a unique opportunity to foster greater collaboration between member states, the EU Drugs Agency, and civil society organisations.' She added, 'Together, we can better address the health and preparedness challenges posed by an evolving and dynamic drugs market.' Minister for Public Health, Wellbeing and the National Drugs Strategy, Jennifer Murnane O'Connor reaffirmed her commitment to a health-led approach, including the proposed health diversion scheme. She welcomed 'the strong endorsement in the evaluation of the health-led response to drug use, including the proposed health diversion scheme for people found in possession of drugs for personal use. I am determined that the scheme will commence as soon as possible, in line with the commitments in the Programme for Government.' Next steps Murnane O'Connor announced the formation of a steering group to draft the next strategy. 'It is my ambition that the successor national drugs strategy will further strengthen the health-led approach to drug use by addressing the health and social needs of people who use drugs, reducing the harms for individuals, families and communities associated with drugs, and supporting recovery from drug addiction,' she said. The review's 10 recommendations include enhancing culturally sensitive services, increasing community engagement, aligning service delivery with regional needs, and investing in monitoring and research systems. It also calls for stronger integration of alcohol treatment services and continued development of alternatives to criminal sanctions. The evaluation follows the 2024 report of the Citizens' Assembly on Drug Use, which issued 36 recommendations spanning prevention, harm reduction, treatment, and recovery. These remain under active consideration by the Joint Oireachtas Committee on Drug Use and are expected to shape the forthcoming strategy. The EU Drugs Strategy 2021–2025 set out a robust, health-oriented framework to tackle drug-related issues across member states, balancing supply reduction with demand-side interventions. Central to the strategy has been harm reduction, international cooperation, and evidence-based policymaking, underpinned by commitments to human rights, gender equality, and public health. Its strategic goals have included enhancing security, expanding access to treatment, and reinforcing governance structures. The strategy also aligns with UN conventions and supports multilateral engagement. Its foremost priority is the disruption and dismantling of high-risk organised crime groups linked to drug trafficking, particularly those operating within or targeting the EU, and addressing their connections to broader security threats. By Brian Maguire
Euractiv
4 days ago
- Euractiv
A vaccine against cancer – but not for everyone
Some EU countries are beating HPV-related cancers, but others fail to provide life-saving measures. When Kim Hulscher sits upright at a table, her right leg swells. This is a lasting effect of lymphedema, a common cancer-related condition she developed after her cervical cancer treatment. 'I have to buy shoes that are twice my size because my foot won't fit into normal ones,' she says. Now, more than a decade after her diagnosis, she is speaking at the European Parliament during a conference titled 'Accelerating Progress Towards the EU's Goal of Eliminating HPV Cancers,' hosted by the European Cancer Organisation and the vice-chair of the Health Committee, Tilly Metz. Hulscher is there as co-chair of the European Society of Gynaecological Oncology – and as a cancer survivor committed to helping spare others what she went through. Hulscher's cervical cancer, like many others, was caused by a type of Human Papillomavirus (HPV), which can often be prevented through vaccination and detected early through screening. Far from elimination Yet Europe is still far from stopping these cancers. According to the World Health Organization, cervical cancer elimination means reducing incidence to fewer than four cases per 100,000 women. The most optimistic projections suggest that Europe could achieve this goal by 2050. In 2022, the ratio stood at 56 per 100,000 across the European Economic Area (EEA), which includes the EU, Iceland, Liechtenstein, and Norway. Around 130,000 women were newly diagnosed, and 14,000 died. HPV-linked head and neck cancers also remain significant causes of mortality. In 2022, 86,000 people were diagnosed, 74% of them men. These cancers caused about 26,000 deaths across the region. Vaccination at a young age is the most effective way to prevent such deaths. Once sexually active, HPV infection is nearly unavoidable. 'It is as contagious as a cold,' said Hulscher. Another participant put it more vividly: 'HPV is like glitter – it gets everywhere: in your car, in your pockets. So it doesn't have to be penetrative sex to catch it.' Often, HPV infections clear up on their own without causing lasting damage, and only about a dozen of the over 200 known HPV types are cancer-causing. However, the only sure way to avoid infection with these is to live like a nun or a monk. Last year, the European Council adopted recommendations urging countries to fully vaccinate at least 90% of girls and significantly increase uptake among boys. All EU member states now offer gender-neutral vaccination. Only five EEA countries – Portugal, Sweden, Cyprus, Iceland, and Norway – have reached the 90% coverage target for girls. 'There is a lot of work to be done,' said Karam Adel, principal expert at the European Centre for Disease Prevention and Control. He also noted a 'huge disparity between West and East,' with some countries reporting female coverage well below 50%. The price of inaction According to conference participants, vaccine scepticism, limited registries, and underfunded national vaccination programmes remain major roadblocks. The benefits of prevention, however, are not only medical but also financial. In a study involving six European countries (Romania, Poland, France, Austria, the Netherlands, and Germany), Maarten J. Postma, professor of medical sciences and an expert in health economics, estimated potential savings of €2.75 billion between 2030 and 2060. All it would take is for these countries to reach the 90% HPV vaccination target by 2030, along with WHO-recommended screening and treatment goals. 'We should conceive vaccination – and prevention in general – not as a cost but rather as an investment,' said Postma. Still, awareness remains low. "Consistently, studies show that whether it's children, young adults, or parents, people are unaware of the consequences of HPV infections," said Adel. He also stressed the importance of ongoing screening, even for those who are vaccinated, as vaccines do not cover all high-risk HPV types. Metz echoed the call for stronger education. "To truly eliminate HPV, we need progressive, inclusive, and scientifically accurate education – because empowering young people with knowledge is one of the most effective forms of prevention," she said. (de)
Euractiv
5 days ago
- Euractiv
Wild Animals Not Pets – The Case for an EU Positive List
Health This video captures highlights from the event: Wild Animals Not Pets – The Case for an EU Positive List. A gathering of policymakers, experts, and animal welfare advocates at the European Parliament to discuss the trade in wild animals and its implications for welfare, health, and biodiversity | 22 Jul 2025 | 12:00 | 1 min. read | video This video captures highlights from the event: Wild Animals Not Pets – The Case for an EU Positive List. A gathering of policymakers, experts, and animal welfare advocates at the European Parliament to discuss the trade in wild animals and its implications for welfare, health, and biodiversity. Speakers reflected on the importance of: Establishing an EU-wide positive list of species permitted as pets Addressing the risks wild animal trade poses to animal welfare, public health, and biodiversity Tackling fragmented national rules and the need for harmonised EU legislation Strengthening EU animal welfare frameworks to better protect wild species At a time when animal welfare and biodiversity face increasing pressures, these insights point to the need for coherent, science-based policies that safeguard both animals and society. Euractiv is part of the Trust Project More from this section
